$VELO

Velo3D, Inc. (VELO): Results of Operations and Financial Condition

Velo3D, Inc. (VELO) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 velo-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Velo3D Announces Second Quarter 2026 Financial Results • Revenue of $20.7 million, up 52.3% year-over-year • Gross margin of 21.5% • Cash and cash equivalents of $91.1 million as of June 30, 2026 • New Livermore Production Ca

Original reporting
Published Aug 11, 2026, 8:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 11, 2026, 8:16 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefEarnings
Primary signal
$VELO
Bullish
medium confidence
Mentioned
$VELO
Relevance
7/10
alphai data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$VELOBullishMed
01

Why it matters

Traders can update expectations for 2026 revenue trajectory and margin trajectory based on the explicit guidance raise, improved gross margin, and higher cash balance, while monitoring execution risk around the Livermore Production Campus ramp.

02

Market read

The filing provides a fresh earnings-and-guidance datapoint plus balance-sheet improvement, which can drive repricing of growth and execution risk for VELO.

03

What to watch

Operating expenses rose to $15.5M in Q2 2026, and the company remains loss-making on a GAAP basis, so investors may focus on whether margin expansion is sustainable as scale increases.

Relevance 7/10Novelty 8/10Timing: after-hours filing on Aug 11, 2026 (SEC 8-K with Q2 results and updated 2026 guidance)

Background

This is an SEC Form 8-K (Item 2.02) with Velo3D’s Q2 2026 financial results and related business updates, including a manufacturing capacity expansion and capital-raising activity.

Company-level read

Ticker impact

$VELOBullishMedium confidence
Context

Velo3D reported Q2 2026 revenue of $20.7M (+52.3% YoY), gross margin 21.5%, and raised 2026 revenue guidance to $65M-$75M.

Expected impact

Near-term bias higher as traders reprice growth and capacity ramp expectations into 2026.

Evidence & confidence

The filing includes multiple decision-relevant datapoints: revenue growth, gross margin expansion, cash increase to $91.1M, and explicit 2026 guidance uplift tied to the Livermore Production Campus capacity expansion.

Market effects

Supports the narrative of improving economics in metal additive manufacturing as capacity expansions translate into higher-margin revenue mix.

Limited, as the disclosure is company-specific though it highlights a new manufacturing campus in Fremont/Livermore.

Moderate for aerospace and defense supply-chain modernization themes, but the impact is primarily VELO-specific.

Counterpoint

The guidance increase may still be contingent on ramp execution at the Livermore Production Campus, so near-term results could be volatile if production timelines slip.

Key entities

  • Velo3D, Inc.

    Additive manufacturing company reporting Q2 2026 results, raising 2026 revenue guidance, and launching a new Livermore Production Campus.

  • Mears Machine Corporation

    Ordered its fifth Velo3D Sapphire XC system, with options for two additional systems to expand distributed manufacturing capacity.

  • Aurelia Technologies

    Strategic partnership to advance metal additive manufacturing for next-generation gas turbine systems.

  • Russell 3000 Index and Russell Microcap Index

    Inclusion noted as strengthening institutional market presence and market exposure.

Related articles

$VELOHighAI 9/10

Why is Velo3D stock surging today?

Velo3D shares rose about 17.2% in pre-open trading after the company reported Q2 2026 results. Revenue was $20.7 million, up 52.3% year over year and above an estimated $13.52 million. Velo3D raised full-year 2026 revenue guidance to $65 million to $75 million and expects positive EBITDA in H2 2026, with gross margin improving to 21.5% and backlog up to $31 million.

$APREMed

Aprea Therapeutics, Inc. (APRE): Results of Operations and Financial Condition

Aprea Therapeutics, Inc. (APRE) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 apre-20260812xex99d1.htm EX-99.1 ​ Exhibit 99.1 ​ Aprea Therapeutics Announces Second Quarter 2026 Financial Results ​ Enrollment in the ongoing Phase 1 dose escalation ACESOT-1051 trial of oral WEE1 inhibitor APR-1051 is accelerating as dose escalation advances Aprea p